Literature DB >> 6262539

Tetrahydrouridine specifically facilitates deoxycytidine incorporation into herpes simplex virus DNA.

T W North, C K Mathews.   

Abstract

As reported by Jamieson and Subak-Sharpe (J. Gen. Virol. 31:303-313, 1976), exogenous deoxycytidine is very poorly incorporated into herpes simplex virus DNA. Here it is shown that this incorporation was dramatically increased in the presence of tetrahydrouridine (THU), a specific inhibitor of cytidine-deoxycytidine deaminase. Thus, the exclusion of deoxycytidine from herpes simplex virus DNA probably results from massive degradation by the deaminase, which is consistent with the observation that in the absence of THU, most of the nucleotides formed from exogenous deoxycytidine are dUMP. The effect of tHU upon deoxycytidine incorporation was specific for herpes simplex virus-infected cells; THU did not increase deoxycytidine incorporation into DNA of uninfected cells. Therefore, one might expect THU to enhance the antiviral activity of 1-beta-D-arabinofuranasylcytosine since this analog is also readily deaminated. However, THU increased both the antiviral activity and the cell toxicity only slightly and to about the same extent. Therefore, the metabolism of 1-beta-D-arabnofuranosylcytosine is different from that of deoxycytidine in herpes simplex virus-infected cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6262539      PMCID: PMC171096     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  THE MULTIPLICATION OF HERPES SIMPLEX VIRUS. II. THE RELATION BETWEEN PROTEIN SYNTHESIS AND THE DUPLICATION OF VIRAL DNA IN INFECTED HEP-2 CELLS.

Authors:  B ROIZMAN; P R ROANE
Journal:  Virology       Date:  1964-02       Impact factor: 3.616

2.  Penetration of mouse fibroblasts by the 5'-phosphate of 9-beta-D-arabinofuranosyladenine and incorporation of the nucleotide into DNA.

Authors:  W Plunkett; L Lapi; P J Ortiz; S S Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1974-01       Impact factor: 11.205

3.  Altered properties of thymidine kinase after infection of mouse fibroblast cells with herpes simplex virus.

Authors:  S Kit; D R Dubbs; M Anken
Journal:  J Virol       Date:  1967-02       Impact factor: 5.103

4.  Altered properties of deoxyribonucleic acid nucleotidyltransferase after infection of mammalian cells with herpes simplex virus.

Authors:  H M Keir; J Hay; J M Morrison; H Subak-Sharpe
Journal:  Nature       Date:  1966-04-23       Impact factor: 49.962

5.  Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse.

Authors:  D H Ho
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

6.  Studies on nucleoside deaminase. Increase in activity in HeLa cell cultures caused by cytosine arabinoside.

Authors:  R Meyers; V G Malathi; R P Cox; R Silber
Journal:  J Biol Chem       Date:  1973-09-10       Impact factor: 5.157

7.  The effect of inhibition of cytidine deaminase by tetrahydrouridine on the utilization of deoxycytidine and 5-bromodeoxycytidine for deoxyribonucleic acid synthesis.

Authors:  G M Cooper; S Greer
Journal:  Mol Pharmacol       Date:  1973-11       Impact factor: 4.436

8.  Studies of the enzymatic deamination of ara-cytidine. V. inhibition in vitro and in vivo by tetrahydrouridine and other reduced pyrimidine nucleosides.

Authors:  G W Camiener
Journal:  Biochem Pharmacol       Date:  1968-09       Impact factor: 5.858

9.  Size, composition, and structure of the deoxyribonucleic acid of herpes simplex virus subtypes 1 and 2.

Authors:  E D Kieff; S L Bachenheimer; B Roizman
Journal:  J Virol       Date:  1971-08       Impact factor: 5.103

10.  Ribonucleotide reductase activity of synchronized KB cells infected with herpes simplex virus.

Authors:  G H Cohen
Journal:  J Virol       Date:  1972-03       Impact factor: 5.103

View more
  1 in total

1.  Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

Authors:  Jan H Beumer; Julie L Eiseman; Robert A Parise; Jeffry A Florian; Erin Joseph; David Z D'Argenio; Robert S Parker; Brittany Kay; Joseph M Covey; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2007-11-15       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.